GleamWall
中文EN

LYEL Lyell Immunopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1806952 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-63.4%
TTM net income YoY21.6%
TTM EPS YoY44.6%
Revenue 3-yr CAGR-93.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,783,580.0%
Net margin-1,701,066.7%
FCF margin-933,100.0%
EBITDA margin-1,723,546.7%

Returns

ROE-97.8%
ROA-74.8%
ROIC (approx.)-138.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets29.6%
Debt / equity0.00x
Current ratio4.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.55x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue4,766.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$36,000$61,000
R&D expense$158.68M$171.60M
SG&A expense$45.13M$52.04M
Operating income-$269.40M-$358.75M
Income tax$0—
Net income-$274.45M-$342.99M
EBITDA-$257.87M-$339.12M
EPS (basic)-16.06-26.23
EPS (diluted)-16.06-26.23
Weighted avg. shares (diluted)17.09M13.07M
Balance sheet
Cash & equivalents$60.18M$107.29M
Short-term investments$187.04M$264.93M
Current assets$260.94M$379.59M
PP&E, net$34.77M$48.20M
Total assets$340.05M$490.86M
Current liabilities$49.41M$53.79M
Total liabilities$91.85M$108.03M
Shareholders' equity$248.20M$382.82M
Shares outstanding21.25M14.74M
Cash flow statement
Operating cash flow-$150.02M-$162.39M
Capital expenditure$780,000$464,000
Free cash flow-$150.80M-$162.86M
Investing cash flow$54.10M$122.42M
Financing cash flow$50.41M$1.33M
Depreciation & amortization$11.54M$19.63M
Stock-based compensation$41.83M$33.14M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.